Web Meeting Info
Join Zoom Meeting https://hl7-org.zoom.us/j/8033561462
Meeting ID: 803 356 1462
Chair: Russell Leftwich or Laura Heermann-Langford or James McClay or James Tcheng or Bruce Bray
Scribe:
Attendance
Name | Affiliation | Name | Affiliation | Name | Affiliation | Name | Affiliation | Name | Affiliation | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
X | Russell Leftwich | InterSystems | ||||||||||||
excused | Laura H Langford | Graphite | ||||||||||||
Jim McClay | U Missouri | |||||||||||||
X | Jimmy Tcheng | Duke Univ | ||||||||||||
X | Dave Pyke | Point Click | ||||||||||||
X | Chris Melo | Philips |
Quorum (Chair +3) met?
HL7 Antitrust Policy
Professional Associations, such as HL7, which bring together competing entities are subject to strict scrutiny under applicable antitrust laws. HL7 recognizes that the antitrust laws were enacted to promote fairness in competition and, as such, supports laws against monopoly and restraints of trade and their enforcement. Each individual participating in HL7 meetings and conferences, regardless of venue, is responsible for knowing the contents of and adhering to the HL7 Antitrust Policy as stated in §05.01 of the Governance and Operations Manual (GOM)
Agenda
- Antitrust Statement
- Review Agenda
- ICHOM Publishing Plan
- Will complete and post content from ballot with intent of voting to publish at meeting April.
- Project Proposals/PSS Reviews https://confluence.hl7.org/display/TPTF
- PSS for AdverseEvent IG in Clinical Trials - discussed incompatibility of definition of Adverse Event in clinical care vs clinical trial - general agreement that a review of this topic wrt FHIR AdverseEvent resouce in a larger forum (WGM quarter) with intent to make a definitive recommendation on whether there should be two separate FHIR Resources for AdverseEvent that distinguish the different concepts.